Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
Open Access
- 1 April 2000
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 109 (1), 89-96
- https://doi.org/10.1046/j.1365-2141.2000.01983.x
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
This publication has 18 references indexed in Scilit:
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The Rationale and Future Potential of Angiogenesis Inhibitors in NeoplasiaDrugs, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1997
- Immunomodulatory assays to study structure-activity relationships of thalidomideImmunopharmacology, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide for the Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1992
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984